If the strategy is to bring PSI-7977 monotherapy to market as a first generation oral compound there are clearly advantages to this line of thinking. By November PSI-7977 will have been through extensive phase 2 testing and it and will move much quicker through late stage testing than the dual nuke combination. That is if monotherapy is a viable option. The lack of interferon should also help expedite the process.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.